These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate. Dragović T; Ajdinović B; Hrvacević R; Ilić V; Magić Z; Andelković Z; Kocev N Vojnosanit Pregl; 2010 Apr; 67(4):273-8. PubMed ID: 20465154 [TBL] [Abstract][Full Text] [Related]
5. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone. Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104 [TBL] [Abstract][Full Text] [Related]
6. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Andersen S; van Nieuwenhoven FA; Tarnow L; Rossing P; Rossing K; Wieten L; Goldschmeding R; Parving HH Kidney Int; 2005 Jun; 67(6):2325-9. PubMed ID: 15882275 [TBL] [Abstract][Full Text] [Related]
7. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Holtkamp FA; de Zeeuw D; Thomas MC; Cooper ME; de Graeff PA; Hillege HJ; Parving HH; Brenner BM; Shahinfar S; Lambers Heerspink HJ Kidney Int; 2011 Aug; 80(3):282-7. PubMed ID: 21451458 [TBL] [Abstract][Full Text] [Related]
8. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106 [TBL] [Abstract][Full Text] [Related]
9. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Andersen S; Jacobsen P; Tarnow L; Rossing P; Juhl TR; Parving HH Nephrol Dial Transplant; 2003 Feb; 18(2):293-7. PubMed ID: 12543883 [TBL] [Abstract][Full Text] [Related]
10. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. Brocco E; Velussi M; Cernigoi AM; Abaterusso C; Bruseghin M; Carraro A; Sambataro M; Piarulli F; Sfriso A; Nosadini R J Nephrol; 2001; 14(6):461-71. PubMed ID: 11783602 [TBL] [Abstract][Full Text] [Related]
11. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Crepaldi G; Carta Q; Deferrari G; Mangili R; Navalesi R; Santeusanio F; Spalluto A; Vanasia A; Villa GM; Nosadini R Diabetes Care; 1998 Jan; 21(1):104-10. PubMed ID: 9538979 [TBL] [Abstract][Full Text] [Related]
12. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116 [TBL] [Abstract][Full Text] [Related]
13. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Rossing K; Christensen PK; Jensen BR; Parving HH Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908 [TBL] [Abstract][Full Text] [Related]
14. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037 [TBL] [Abstract][Full Text] [Related]
15. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Rossing P; Hommel E; Smidt UM; Parving HH Diabetologia; 1994 May; 37(5):511-6. PubMed ID: 8056190 [TBL] [Abstract][Full Text] [Related]